Go to JCI Insight
Jci spelled out white on transparent.20160208
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews...
    • Mitochondrial dysfunction in disease (Aug 2018)
    • Lipid mediators of disease (Jul 2018)
    • Cellular senescence in human disease (Apr 2018)
    • Fibrosis (Jan 2018)
    • Glia and Neurodegeneration (Sep 2017)
    • Transplantation (Jun 2017)
    • Nuclear Receptors (Apr 2017)
    • View all review series...
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Scientific Show Stoppers
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

Jci only white

  • About
  • Editors
  • Consulting Editors
  • For authors
  • Current issue
  • Past issues
  • By specialty
  • Subscribe
  • Alerts
  • Advertise
  • Contact
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • Brief Reports
  • Technical Advances
  • Commentaries
  • Editorials
  • Hindsight
  • Review series
  • Reviews
  • The Attending Physician
  • First Author Perspectives
  • Scientific Show Stoppers
  • Top read articles
  • Concise Communication
Top
  • View PDF Adobe pdf file icon
  • Download citation information
  • Send a letter
  • License information
  • Standard abbreviations
  • Article usage
  • Citations to this article
  • Share this article
  • Need Help? E-mail the JCI
  • Top
  • Abstract
  • Version history
Advertisement
Amendment history:
  • Correction (July 1972)

Free access | 10.1172/JCI106467

Cyclic 3′,5′-adenosine monophosphate in human blood platelets: II. Effect of N6-2′-0-dibutyryl cyclic 3′,5′-adenosine monophosphate on platelet function

Edwin W. Salzman and Linda Levine

Department of Surgery, Harvard Medical School, Boston, Massachusetts 02215

Surgical Service, Beth Israel Hospital, Boston, Massachusetts 02215

Find articles by Salzman, E. in: JCI | PubMed | Google Scholar

Department of Surgery, Harvard Medical School, Boston, Massachusetts 02215

Surgical Service, Beth Israel Hospital, Boston, Massachusetts 02215

Find articles by Levine, L. in: JCI | PubMed | Google Scholar

First published January 1, 1971 - More info

Published in Volume 50, Issue 1 on January 1, 1971
J Clin Invest. 1971;50(1):131–141. https://doi.org/10.1172/JCI106467.
Copyright © 1971, The American Society for Clinical Investigation.

First published January 1, 1971 - Version history
Abstract

The relation of cyclic 3′,5′-adenosine monophosphate to platelet function has been studied by investigating the influence of this compound and of its N6-2′-0-dibutyryl derivative on platelet aggregation and other aspects of platelet behavior after demonstration of adenyl cyclase activity in disrupted platelets.

Dibutyryl cyclic AMP inhibited platelet aggregation induced by ADP, epinephrine, collagen, and thrombin. Cyclic AMP was also inhibitory but was less effective. The platelet “release reaction” was also inhibited; specifically, there was inhibition of the induction of platelet factor 3 activity and of the release of labeled 5-hydroxytryptamine. Platelet swelling produced by ADP was not inhibited.

The action of dibutyryl cyclic AMP did not result from contamination with 5′-AMP, nor was it attributable to production of 5′-AMP by plasma enzymes. Dibutyryl cyclic AMP was degraded to 2′-O-monobutyryl cyclic AMP and to cyclic AMP in plasma, but plasma exhibited no cyclic nucleotide phosphodiesterase activity, and the production of 5′-AMP did not occur. The in vitro effects of dibutyryl cyclic AMP were associated with uptake of the compound by platelets.

Adenyl cyclase activity of platelet homogenates was demonstrated with production of 9.27 × 10-11 (±2.62 × 10-11) mole cyclic AMP per min per 1010 platelets. The activity was increased by NaF and by prostaglandin PGE1 and was decreased by epinephrine. The effect of epinephrine was blocked by phentolamine but not by propanolol. Adenyl cyclase activity was also inhibited by collagen, 5-hydroxytryptamine, and thrombin. ADP, dibutyryl cyclic AMP, and cyclic AMP did not alter adenyl cyclase activity.

These observations are consistent with the hypothesis that platelet aggregation is favored by a decrease in platelet cyclic AMP and inhibited by an increase in cyclic AMP.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 131
page 131
icon of scanned page 132
page 132
icon of scanned page 133
page 133
icon of scanned page 134
page 134
icon of scanned page 135
page 135
icon of scanned page 136
page 136
icon of scanned page 137
page 137
icon of scanned page 138
page 138
icon of scanned page 139
page 139
icon of scanned page 140
page 140
icon of scanned page 141
page 141
Version history
  • Version 1 (January 1, 1971): No description

Article tools

  • View PDF Adobe pdf file icon
  • Download citation information
  • Send a letter
  • License information
  • Standard abbreviations
  • Article usage
  • Citations to this article
  • Share this article
  • Need Help? E-mail the JCI

Go to:

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement
Follow JCI: Facebook logo white Twitter logo v2 Rss icon
Copyright © 2018 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts